Back to Top
Larcaviximab Biosimilar - Research Grade
Frequently Bought Together
Loading...
Larcaviximab Biosimilar - Research Grade
Endotoxin
≤ 1.0 EU/mg as determined by the LAL method
Purity
>90% by SDS-PAGE
Species Reactivity
Human
Target
Zaire Ebola virus
Concentration
>1mg/ml
Isotype
IgG1 - kappa
Host
CHO Cells
Antibodies Against The Same Target
Sequence
https://www.imgt.org/mAb-DB/
Buffer
ICH3002
Shipping Conditions
Blue ice
Background
Antibodies directed against the Zaire Ebola virus glycoprotein are central tools for filovirus neutralization research and vaccine evaluation. This human IgG1, kappa reagent is an unconjugated, non-therapeutic analog of larcaviximab that recognizes the Zaire Ebola virus antigen for functional and infectious-disease studies. It is prepared in a low-endotoxin format suited to in vivo experiments and manufactured at scalable milligram-to-gram volumes to keep bulk and high-throughput pipelines supplied. Provided for research use only (RUO), it is appropriate as a positive binding control and active reagent in neutralization assays, antigen-detection panels, and preclinical models of filovirus infection.
Purification Method
This monoclonal antibody was purified using Protein A
Formulation
Sterile, preservative-free, solution in PBS. BSA and Azide free.
Storage
This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.
Applications
Functional Assays
Application Notes
This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.
Use
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Delivery Time
3-4 weeks
Faq (q&a)
Q: Is the Larcaviximab biosimilar available in gram quantities?
A: Yes — it is supplied in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.
Q: Is this research-grade Larcaviximab biosimilar suitable for in vivo studies?
A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).
Q: What does the Larcaviximab biosimilar target?
A: It is a non-therapeutic biosimilar of Larcaviximab used as a binding and neutralization reagent against Zaire Ebola virus; for research use only.
Write Your Own Review
Is the Larcaviximab biosimilar available in gram quantities?
Yes — it is supplied in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.
Is this research-grade Larcaviximab biosimilar suitable for in vivo studies?
Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).
What does the Larcaviximab biosimilar target?
It is a non-therapeutic biosimilar of Larcaviximab used as a binding and neutralization reagent against Zaire Ebola virus; for research use only.
Who Viewed This Also Viewed
Add recommended extras
-
In Vivo Buffer pH7.2$112.50
